Compare ANVS & MCHX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANVS | MCHX |
|---|---|---|
| Founded | 2008 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.4M | 67.3M |
| IPO Year | 2019 | 2003 |
| Metric | ANVS | MCHX |
|---|---|---|
| Price | $1.20 | $1.28 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $10.50 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 43.9K |
| Earning Date | 11-11-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.39 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $90,291,000.00 |
| Revenue This Year | N/A | $17.69 |
| Revenue Next Year | N/A | $29.82 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.04 | $1.15 |
| 52 Week High | $5.50 | $2.04 |
| Indicator | ANVS | MCHX |
|---|---|---|
| Relative Strength Index (RSI) | 38.01 | 38.24 |
| Support Level | $1.04 | $1.15 |
| Resistance Level | $2.43 | $1.61 |
| Average True Range (ATR) | 0.09 | 0.11 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 38.46 | 48.57 |
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
Marchex Inc provides AI-based conversational intelligence and analytics solutions that generate insights from customer communications data. The company's products support sales, marketing, and executive teams in analyzing customer interactions across communication channels and informing business decisions. It serves companies operating in business-to-business-to-consumer (B2B2C) markets across multiple industries like automotive, home services, healthcare, real estate, and advertising. The company operates in a single segment: conversational analytics and related solutions. The company generates the majority of revenue from its conversational intelligence product offerings. Geographically, it generates the maximum revenue from the United States.